Substance P and CGRP mediate motor response of rabbit colon to capsaicin.
Primary afferent nerve terminals located in the mammalian gut wall may play a role in region-specific modulation of gastrointestinal motility. In the present study, we sought to characterize the effect of neuropeptides released from these afferents by capsaicin (CAP) on contractile activity of smooth muscle from the distal rabbit colon. CAP caused a release of acetylcholine and immunoreactivity for substance P (SP) and calcitonin gene-related peptide (CGRP) from the muscle coat. CAP caused a dose-dependent transient stimulation of longitudinal muscle contractions, followed by prolonged inhibition of spontaneous but not stimulated contractile activity. The initial stimulation was abolished by the SP antagonist spantide and by atropine. The inhibitory effect was reduced by repeated exposure of muscle to CGRP. The effect of CGRP on spontaneous contractions differed between longitudinal and circular muscle. In longitudinal muscle, a stimulation was preceded by a transient inhibition, whereas in circular muscle, only inhibition was seen. Both effects were resistant to tetrodotoxin. Repeated exposure of circular but not longitudinal muscle to CGRP resulted in a disappearance of the peptide's inhibitory effect. Exogenously applied CGRP was only a weak antagonist of contractions stimulated by SP and bethanechol. These findings suggest that in the rabbit colon at least the following two neuropeptides are released from CAP-sensitive nerve fibers: a neurokinin peptide from nerve terminals located within the myenteric plexus and CGRP from terminals probably located within the circular muscle layer.
Mayer
E A
EA
Department of Medicine, Harbor-University of California, Los Angeles.
Koelbel
C B
CB
Snape
W J
WJ
Eysselein
V
V
Ennes
H
H
Kodner
A
A
D000109:Acetylcholine / Q000378:metabolism; D000255:Adenosine Triphosphate / Q000494:pharmacology; D000344:Afferent Pathways / Q000187:drug effects / Q000502:physiology; D000818:Animals; D001285:Atropine / Q000494:pharmacology; D015740:Calcitonin Gene-Related Peptide / Q000378:metabolism* / Q000494:pharmacology; D002211:Capsaicin / Q000494:pharmacology*; D003106:Colon / Q000187:drug effects / Q000294:innervation / Q000502:physiology*; D005769:Gastrointestinal Motility / Q000187:drug effects*; D018738:Hexamethonium; D006584:Hexamethonium Compounds / Q000494:pharmacology; D066298:In Vitro Techniques; D007700:Kinetics; D008297:Male; D009130:Muscle, Smooth / Q000187:drug effects / Q000294:innervation / Q000502:physiology; D009474:Neurons / Q000187:drug effects / Q000502:physiology*; D011817:Rabbits; D013373:Substance P / Q000378:metabolism* / Q000494:pharmacology; D013779:Tetrodotoxin / Q000494:pharmacology
D006584:Hexamethonium Compounds; D013373:Substance P; D018738:Hexamethonium; D013779:Tetrodotoxin; D001285:Atropine; D000255:Adenosine Triphosphate; D015740:Calcitonin Gene-Related Peptide; D000109:Acetylcholine; D002211:Capsaicin